Open Access

Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens

  • Authors:
    • Yu-Nung Chen
    • Cheng-Yen Shih
    • Shu-Lin Guo
    • Chih-Yi Liu
    • Ming-Hung Shen
    • Shih-Chang Chang
    • Wei-Chi Ku
    • Chi-Cheng Huang
    • Chi-Jung Huang
  • View Affiliations

  • Published online on: February 7, 2023     https://doi.org/10.3892/br.2023.1604
  • Article Number: 22
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer (CRC) is the most common gastrointestinal malignancy worldwide. The poor specificity and sensitivity of the fecal occult blood test has prompted the development of CRC‑related genetic markers for CRC screening and treatment. Gene expression profiles in stool specimens are effective, sensitive and clinically applicable. Herein, a novel advantage of using cells shed from the colon is presented for cost‑effective CRC screening. Molecular panels were generated through a series of leave‑one‑out cross‑validation and discriminant analyses. A logistic regression model following reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and immunohistochemistry was used to validate a specific panel for CRC prediction. The panel, consisting of ubiquitin‑conjugating enzyme E2 N (UBE2N), inosine monophosphate dehydrogenase 1 (IMPDH1), dynein cytoplasmic 1 light intermediate chain 1 (DYNC1LI1) and phospholipase A and acyltransferase 2 (HRASLS2), accurately recognized patients with CRC and could thus be further investigated as a potential prognostic and predictive biomarker for CRC. UBE2N, IMPDH1 and DYNC1LI1 expression levels were upregulated and HRASLS2 expression was downregulated in CRC tissues. The predictive power of the panel was 96.6% [95% confidence interval (CI), 88.1‑99.6%] sensitivity and 89.7% (95% CI, 72.6‑97.8%) specificity at a predicted cut‑off value at 0.540, suggesting that this four‑gene panel testing of stool specimens can faithfully mirror the state of the colon. On the whole, the present study demonstrates that screening for CRC or cancer detection in stool specimens collected non‑invasively does not require the inclusion of an excessive number of genes, and colonic defects can be identified via the detection of an aberrant protein in the mucosa or submucosa.
View Figures
View References

Related Articles

Journal Cover

March-2023
Volume 18 Issue 3

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen Y, Shih C, Guo S, Liu C, Shen M, Chang S, Ku W, Huang C and Huang C: Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens. Biomed Rep 18: 22, 2023.
APA
Chen, Y., Shih, C., Guo, S., Liu, C., Shen, M., Chang, S. ... Huang, C. (2023). Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens. Biomedical Reports, 18, 22. https://doi.org/10.3892/br.2023.1604
MLA
Chen, Y., Shih, C., Guo, S., Liu, C., Shen, M., Chang, S., Ku, W., Huang, C., Huang, C."Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens". Biomedical Reports 18.3 (2023): 22.
Chicago
Chen, Y., Shih, C., Guo, S., Liu, C., Shen, M., Chang, S., Ku, W., Huang, C., Huang, C."Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens". Biomedical Reports 18, no. 3 (2023): 22. https://doi.org/10.3892/br.2023.1604